Pharmaceutical Executive-01-01-2011

Pharmaceutical Executive
From the Editor

February 04, 2011

"Tops in Fraud" is a ruinous moniker for pharma-a business so dependent on basic issues of trust, integrity, quality and safety

Pharmaceutical Executive

The mediterranean nation has endeared itself to foreign businesses over the past decades, adtively positioning itself as an appealing epicenter of global pharma interest

Pharmaceutical Executive

The mediterranean nation has endeared itself to foreign businesses over the past decades, adtively positioning itself as an appealing epicenter of global pharma interest

Pharmaceutical Executive
Columns

January 01, 2011

Pharma companies will assess health reform, negotiate user fees and keep an eye on federal prosecutors in the year ahead

Pharmaceutical Executive
Columns

January 01, 2011

Incorporating the proper blend of media into your marketing initiatives will help to increase the flexibility and success of your campaigns

Pharmaceutical Executive

US Pharmacopeia has launched an ambitious moderniation campaign to ensure its standards keep pace with changes in the blobal marketplace

Pharmaceutical Executive
Features

January 01, 2011

A surve of leading experts reveals 2011's sobering reality and the trends that smart drugmakers will follow into the next decade

Pharmaceutical Executive
Features

January 01, 2011

Building the commercial and policy base for effective collaboration in biotech

Pharmaceutical Executive

Amgen's hub-and-spoke system combines control at home with the flexibility to respond to local needs

Pharmaceutical Executive
From the Editor

January 01, 2011

"Tops in Fraud" is a ruinous moniker for pharma-a business so dependent on basic issues of trust, integrity, quality and safety

Pharmaceutical Executive
Columns

January 01, 2011

It's a new year. Even pharma, with its glacial timelines, has its "Out with the old, in with the new" moment. Welcome to 2011!

Pharmaceutical Executive

The mediterranean nation has endeared itself to foreign businesses over the past decades, adtively positioning itself as an appealing epicenter of global pharma interest